Cancer-Gene Test Boosts Myriad's Sales

New data indicates risk of invasive breast cancer in women with either BRCA mutation maybe less than previuosly thought This new information will adversely impact Myriad's business

A new study published in the Journal of the American Medical Association estimated a lower risk of developing breast cancer by the age of 70 in women carrying mutations in one of two genes (BRAC1 and BRAC2).  This comes at the same time as Myriad Genetics (MYGN(NMS:MYGN)) is marketing their BRAC1/BRAC2 test.  Breast cancer is responsible for approximately 42,000 deaths in the US each...

Myriad Genetics Inc. went directly to the patients who then were tested whether the tests were indicated or paid for by insurers or out of their own pockets. If patients have "medical savings accts" as suggested by various political candidates, right or wrong patients will want it with this kind of advertising pressure.